Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 640-645

  Sorrentino, Flavia ^a,b   Del Rio, Ruben Gonzalez ^b   Zheng, Xingji ^a   Matilla, Jesus Presa ^b   Gomez, Pedro Torres ^b   Hoyos, Maria Martinez ^b   Herran, Maria Esther Perez ^b   Losana, Alfonso Mendoza ^b   Av Gay, Yossef ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GSK   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GREEN FLUORESCENT PROTEIN; GSK 1385423A; GSK 1589671A; GSK 1589673A; GSK 1826247A; GSK 1941290A; GSK 1985270A; GSK 2043267A; GSK 937213A; GSK 937733A; GW 623128X; ISONIAZID; LEVOFLOXACIN; LINEZOLID; LUCIFERASE; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG IDENTIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TUBERCULOSIS; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEP-G2 CELL LINE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; CELL LINE; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUCIFERASES; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84957927137     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01920-15     Document Type: Article

References (31)

1. World Health Organization. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland. www.who.int/tb/publications/global-report/en/.
2. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, McNeeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
3. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366:2151-2160. http://dx.doi.org/10.1056/NEJMoa1112433.
4. Mdluli K, Kaneko T, Upton A. 2015. The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb Perspect Med 5:a021154. http://dx.doi.org/10.1101/cshperspect.a021154.
5. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, Gomes A, Rustad T, Dolganov G, Glotova I, Abeel T, Mahwinney C, Kennedy AD, Allard R, Brabant W, Krueger A, Jaini S, Honda B, Yu WH, Hickey MJ, Zucker J, Garay C, Weiner B, Sisk P, Stolte C, Winkler J K, Van de Peer Y, Iazzetti P, Camacho D, Dreyfuss J, Liu Y, Dorhoi A, Mollenkopf HJ, Drogaris P, Lamontagne J, Zhou Y, Piquenot J, Park ST, Raman S, Kaufmann SH, Mohney RP, Chelsky D, Moody DB, Sherman DR, Schoolnik GK. 2013. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 499:178-183. http://dx.doi.org/10.1038/nature12337.
6. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19:1157-1160. http://dx.doi.org/10.1038/nm.3262.
7. Queval CJ, Song OR, Delorme V, Iantomasi R, Veyron-Churlet R, Deboosere N, Landry V, Baulard A, Brodin P. 2014. A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. J Vis Exp 83:e51114. http://dx.doi.org/10.3791/51114.
8. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, Rubin EJ, Hung DT. 2014. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 10:e1003946. http://dx.doi.org/10.1371/journal.ppat.1003946.
9. VanderVen BC, Fahey RJ, Lee W, Liu Y, Abramovitch RB, Memmott C, Crowe AM, Eltis LD, Perola E, Deininger DD, Wang T, Locher CP, Russell DG. 2015. Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog 11:e1004679. http://dx.doi.org/10.1371/journal.ppat.1004679.
10. Silva-Miranda M, Ekaza E, Breiman A, Asehnoune K, Barros-Aguirre D, Pethe K, Ewann F, Brodin P, Ballell-Pages L, Altare F. 2015. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:693-697. http://dx.doi.org/10.1128/AAC.03705-14.
11. Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Rottger S, Zhang M, Szekely R, Greff Z, Orfi L, Szabadkai I, Pato J, Keri G, Cole ST. 2014. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host Microbe 16:538-548. http://dx.doi.org/10.1016/j.chom.2014.09.008.
12. North RJ, Izzo AA. 1993. Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J Exp Med 177:1723-1733.
13. Chanwong S, Maneekarn N, Makonkawkeyoon L, Makonkawkeyoon S. 2007. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages. Tuberculosis (Edinb) 87:130-133. http://dx.doi.org/10.1016/j.tube.2006.06.001.
14. Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel SS, Back DJ, Khoo SH. 2007. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 87:248-255. http://dx.doi.org/10.1016/j.tube.2006.12.001.
15. Rey-Jurado E, Tudo G, Soy D, Gonzalez-Martin J. 2013. Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model. Int J Antimicrob Agents 42:524-530. http://dx.doi.org/10.1016/j.ijantimicag.2013.07.014.
16. Zhang Y, Scorpio A, Nikaido H, Sun Z. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181:2044-2049.
17. Shi W, Zhang X, Jiang X, Yuan H, Lee J S, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
18. Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR. 2012. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A 109:15001-15005. http://dx.doi.org/10.1073/pnas.1203636109.
19. Heifets L, Higgins M, Simon B. 2000. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4:491-495.
20. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. http://dx.doi.org/10.1177/108705719900400206.
21. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, Barroso V, Blanco D, Crespo B, Escribano J, Gonzalez R, Lozano S, Huss S, Santos-Villarejo A, Martin-Plaza JJ, Mendoza A, Rebollo-Lopez MJ, Remuiñán-Blanco M, Lavandera JL, Perez-Herran E, Gamo-Benito FJ, Garcia-Bustos JF, Barros D, Castro JP, Cammack N. 2013. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMed-Chem 8:313-321. http://dx.doi.org/10.1002/cmdc.201200428.
22. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7:e1002251. http://dx.doi.org/10.1371/journal.ppat.1002251.
23. Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, Trauner A, Wallis D, Galaviz S, Huttenhower C, Sacchettini JC, Behar SM, Rubin EJ. 2013. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155:1296-1308. http://dx.doi.org/10.1016/j.cell.2013.10.045.
24. Ehrt S, Rhee K, Schnappinger D. 2015. Mycobacterial genes essential for the pathogen's survival in the host. Immunol Rev 264:319-326. http://dx.doi.org/10.1111/imr.12256.
25. Weiss G, Schaible UE. 2015. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev 264:182-203. http://dx.doi.org/10.1111/imr.12266.
26. Wickramasinghe SN. 1987. Evidence of drug metabolism by macrophages: possible role of macrophages in the pathogenesis of drug-induced tissue damage and in the activation of environmental procarcinogens. Clin Lab Haematol 9:271-280. http://dx.doi.org/10.1111/j.1365-2257.1987.tb00091.x.
27. Baik J, Rosania GR. 2011. Molecular imaging of intracellular drug-membrane aggregate formation. Mol Pharm 8:1742-1749. http://dx.doi.org/10.1021/mp200101b.
28. Baik J, Rosania GR. 2012. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS One 7:e47494. http://dx.doi.org/10.1371/journal.pone.0047494.
29. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
30. Remuiñán MJ, Perez-Herran E, Rullas J, Alemparte C, Martinez-Hoyos M, Dow DJ, Afari J, Mehta N, Esquivias J, Jimenez E, Ortega-Muro F, Fraile-Gabaldon MT, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Minick DJ, Cacho M, Rebollo-Lopez MJ, Gonzalez C, Sousa V, Angulo-Barturen I, Mendoza-Losana A, Barros D, Besra GS, Ballell L, Cammack N. 2013. Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 8:e60933. http://dx.doi.org/10.1371/journal.pone.0060933.
31. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Kordulakova J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. 2012. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8:334-341. http://dx.doi.org/10.1038/nchembio.794.